Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,405.45 -94.15 (-1.26%) BTC-USD
27,439.41 -861.31 (-3.04%) CMC Crypto 200
597.33 -21.06 (-3.41%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 0.7397 |
| Open | 0.7371 |
| Bid | 0.6905 x 4000 |
| Ask | 0.7799 x 1100 |
| Day's range | 0.6918 - 0.7549 |
| 52-week range | 0.6918 - 3.4400 |
| Volume | |
| Avg. volume | 612,826 |
| Market cap | 77.671M |
| Beta (5Y monthly) | 1.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0950 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.38 |
- Zacks
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
- Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
DURHAM, N.C., March 02, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.
